Sugi Predict

Sugi Predict / Compounds / SCHEMBL875601

SCHEMBL875601

SCHEMBL875601

O=Cc1ccc(Oc2cncnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.54
▸ ALDH1A1 P00352 8/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ LMNA P02545 1/20 0.52
▸ PARP10 Q53GL7 1/20 0.50
▸ PARP3 Q9Y6F1 1/20 0.50
▸ CYP2A6 P11509 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ CASP6 P55212 1/20 0.44
▸ ALDH1A3 P47895 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ STS P08842 1/20 0.41
▸ DRD1 P21728 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5050902 0.82 PARP10 (0.65) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL1663469 0.82 PARP10 (0.65) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL31238435 0.79 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL433465 0.79 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL2770770 0.79 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL2537809 0.78 SRC (0.47) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL30302069 0.78 SRC (0.47) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL875581 0.77 ACACB (0.43) KDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL1713491 0.77 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2LMNAPARP10
SCHEMBL875005 0.77 PPARG (0.48) KDM4EALDH1A1SMN1; SMN2LMNAPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2771337-B1 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2017-08-02 — — EP disclosed
US-8957068-B2 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH NOVARTIS AG (CH) 2015-02-17 — — US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 — — US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 — — US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 — — US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 — — US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 — — US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 — — US disclosed
EP-2771337-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH Novartis AG (CH) 2014-09-03 — — EP disclosed
US-20140235620-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2014-08-21 — — US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 — — US disclosed
WO-2013046136-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2013-04-04 — — WO disclosed
US-20120232101-A1 Novel Compounds CHAPMAN DAVID (SE) 2012-09-13 — — US disclosed
US-8183251-B2 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2012-05-22 — — US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 — — WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 — — WO disclosed
EP-2097406-B1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS ASTRAZENECA AB (SE) 2011-07-20 — — EP disclosed
EP-2097406-A1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS Astra Zeneca AB (SE) 2009-09-09 — — EP disclosed
US-20080221139-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-09-11 — — US disclosed
WO-2008065393-A1 HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS ASTRAZENECA AB (SE) 2008-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 KDM4E 4272/4885ALDH1A1 3675/4885SMN1; SMN2 4240/4885
US-20080221139-A1 Novel Compounds MMP9, MMP2, MMP1 KDM4E 1320/4885ALDH1A1 282/4885SMN1; SMN2 1975/4885
US-20120232101-A1 Novel Compounds MMP9, MMP2, MMP1 KDM4E 1320/4885ALDH1A1 282/4885SMN1; SMN2 1975/4885
US-20140235620-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH IDH1, IDH3A, IDH3B KDM4E 442/4885ALDH1A1 325/4885SMN1; SMN2 886/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 KDM4E 4272/4885ALDH1A1 3675/4885SMN1; SMN2 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.